• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

5-羟色胺转运体(SLC6A4)和 5-羟色胺受体 2A(HTR2A)基因多态性的相互作用预测文拉法辛 XR 治疗广泛性焦虑障碍的反应。

Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder.

机构信息

1] Psychiatric Pharmacogenetics Laboratory, Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA [2] Mood and Anxiety Disorders Section, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.

出版信息

Pharmacogenomics J. 2013 Oct;13(5):464-9. doi: 10.1038/tpj.2012.33. Epub 2012 Aug 21.

DOI:10.1038/tpj.2012.33
PMID:22907732
Abstract

Variation in genes involved in serotonergic signaling is thought to be associated with antidepressant treatment response in generalized anxiety disorder (GAD). We examined a possible interaction between the serotonin transporter gene (SLC6A4) 5-HTTLPR/rs25531 haplotype and the serotonin 2A receptor gene (HTR2A) single-nucleotide polymorphism (SNP) rs7997012 in antidepressant treatment outcome in GAD. Patients diagnosed with GAD received venlafaxine XR treatment as part of an 18-month relapse prevention study. Genotypes obtained for the 5-HTTLPR/rs25531 (La/La, La/S or S/S) haplotype and rs7997012 SNP (G or A) in the European American population (n=112) were used for pharmacogenetic analysis. Our data show that subjects with genotypes La/La+G/G or La/La+G/A (n=28) had significantly lower Hamilton Anxiety Scale (HAM-A) scores than those with genotypes La/S+A/A or S/S+A/A (n=12) at 6 months (HAM-A difference=10.7; P<0.0001). Single-marker analysis only showed HAM-A differences of 4.3 (5-HTTLPR/rs25531: La/La versus La/S+S/S) and 4.8 (rs7997012: G/G+G/A versus A/A), showing for the first time a significant gene-gene interaction between these markers.

摘要

基因在血清素能信号传导中的变异被认为与广泛性焦虑障碍(GAD)的抗抑郁治疗反应有关。我们研究了血清素转运蛋白基因(SLC6A4)5-HTTLPR/rs25531 单倍型与 5-羟色胺 2A 受体基因(HTR2A)单核苷酸多态性(SNP)rs7997012 在 GAD 抗抑郁治疗结果中的可能相互作用。被诊断患有 GAD 的患者接受文拉法辛 XR 治疗,作为 18 个月复发预防研究的一部分。在欧洲裔美国人(n=112)中获得了 5-HTTLPR/rs25531(La/La、La/S 或 S/S)单倍型和 rs7997012 SNP(G 或 A)的基因型,用于药物遗传学分析。我们的数据表明,基因型为 La/La+G/G 或 La/La+G/A(n=28)的患者在 6 个月时的汉密尔顿焦虑量表(HAM-A)评分显著低于基因型为 La/S+A/A 或 S/S+A/A(n=12)的患者(HAM-A 差值=10.7;P<0.0001)。单标记分析仅显示 HAM-A 的差异为 4.3(5-HTTLPR/rs25531:La/La 与 La/S+S/S)和 4.8(rs7997012:G/G+G/A 与 A/A),这是首次表明这些标记物之间存在显著的基因-基因相互作用。

相似文献

1
Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder.5-羟色胺转运体(SLC6A4)和 5-羟色胺受体 2A(HTR2A)基因多态性的相互作用预测文拉法辛 XR 治疗广泛性焦虑障碍的反应。
Pharmacogenomics J. 2013 Oct;13(5):464-9. doi: 10.1038/tpj.2012.33. Epub 2012 Aug 21.
2
Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder.5-羟色胺受体 2A(HTR2A)基因多态性预测文拉法辛 XR 治疗广泛性焦虑障碍的反应。
Pharmacogenomics J. 2013 Feb;13(1):21-6. doi: 10.1038/tpj.2011.47. Epub 2011 Oct 18.
3
Association analysis between the A118G polymorphism in the OPRM1 gene and treatment response to venlafaxine XR in generalized anxiety disorder.广泛性焦虑障碍患者中OPRM1基因A118G多态性与文拉法辛缓释剂治疗反应的关联分析
Hum Psychopharmacol. 2013 May;28(3):258-62. doi: 10.1002/hup.2317. Epub 2013 May 8.
4
Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: data from a randomized controlled trial.老年人中常见的选择性5-羟色胺再摄取抑制剂副作用与5-羟色胺转运体和受体的基因多态性相关:一项随机对照试验的数据
Am J Geriatr Psychiatry. 2014 Oct;22(10):971-9. doi: 10.1016/j.jagp.2013.07.003. Epub 2013 Sep 8.
5
Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults.5-羟色胺转运体基因多态性与艾司西酞普兰治疗老年广泛性焦虑障碍的疗效关系。
J Clin Psychopharmacol. 2010 Dec;30(6):672-7. doi: 10.1097/jcp.0b013e3181fc2bef.
6
Association analysis between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and treatment response to venlafaxine XR in generalized anxiety disorder.脑源性神经营养因子(BDNF)基因 Val66Met 多态性与文拉法辛 XR 治疗广泛性焦虑障碍的疗效相关性分析。
Neurosci Lett. 2011 Oct 10;503(3):200-2. doi: 10.1016/j.neulet.2011.08.035. Epub 2011 Aug 26.
7
Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.文拉法辛缓释胶囊治疗非抑郁广泛性焦虑障碍门诊患者的疗效:一项为期6个月的随机对照试验。
JAMA. 2000 Jun 21;283(23):3082-8. doi: 10.1001/jama.283.23.3082.
8
Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine.5-羟色胺转运体基因多态性与文拉法辛短期治疗反应的相关性。
Neuropsychobiology. 2010 Aug;62(3):198-206. doi: 10.1159/000319362. Epub 2010 Jul 22.
9
Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder.文拉法辛缓释片治疗广泛性焦虑症患者后的症状改善模式。
J Clin Psychiatry. 2001 Nov;62(11):888-93. doi: 10.4088/jcp.v62n1109.
10
Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.文拉法辛缓释剂治疗伴有共病广泛性焦虑障碍的重度抑郁症患者的疗效
J Clin Psychiatry. 2001 Jul;62(7):523-9. doi: 10.4088/jcp.v62n07a04.

引用本文的文献

1
Genetic Inactivation of the Serotonin Transporter Dysregulates Expression of Neurotransmission Genes and Genome-Wide DNA Methylation Levels in the Medial Prefrontal Cortex of Male Rats During Postnatal Development.在出生后发育过程中,雄性大鼠内侧前额叶皮质中血清素转运体的基因失活会失调神经传递基因的表达和全基因组DNA甲基化水平。
Dev Neurobiol. 2025 Jul;85(3):e22973. doi: 10.1002/dneu.22973.
2
Serotonin Transporter Genetic Variation and Antidepressant Response and Tolerability: A Systematic Review and Meta-Analysis.血清素转运体基因变异与抗抑郁药反应及耐受性:一项系统评价与荟萃分析。
J Pers Med. 2021 Dec 9;11(12):1334. doi: 10.3390/jpm11121334.
3
Pharmacodynamic Gene Testing in Prader-Willi Syndrome.
普拉德-威利综合征的药效基因检测
Front Genet. 2020 Nov 20;11:579609. doi: 10.3389/fgene.2020.579609. eCollection 2020.
4
Pharmacotherapies and personalized medicine for alcohol use disorder: a review.药物治疗和个体化医学在酒精使用障碍中的应用:综述。
Pharmacogenomics. 2020 Oct;21(15):1117-1138. doi: 10.2217/pgs-2020-0079. Epub 2020 Aug 18.
5
Genetics of generalized anxiety disorder and related traits.广泛性焦虑障碍及相关特质的遗传学
Dialogues Clin Neurosci. 2017 Jun;19(2):159-168. doi: 10.31887/DCNS.2017.19.2/kdomschke.
6
Biological markers of generalized anxiety disorder.广泛性焦虑障碍的生物学标志物。
Dialogues Clin Neurosci. 2017 Jun;19(2):147-158. doi: 10.31887/DCNS.2017.19.2/dnutt.
7
Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review.焦虑障碍的长期药物治疗:一项更新的系统评价。
Curr Psychiatry Rep. 2016 Mar;18(3):23. doi: 10.1007/s11920-016-0668-3.
8
Biological predictors of pharmacological therapy in anxiety disorders.焦虑症药物治疗的生物学预测指标
Dialogues Clin Neurosci. 2015 Sep;17(3):305-17. doi: 10.31887/DCNS.2015.17.3/emaron.
9
The 5-HTTLPR confers susceptibility to anorexia nervosa in Han Chinese: evidence from a case-control and family-based study.5-羟色胺转运体基因连锁多态性区域(5-HTTLPR)与汉族人群神经性厌食症易感性相关:一项病例对照研究及家系研究证据
PLoS One. 2015 Mar 18;10(3):e0119378. doi: 10.1371/journal.pone.0119378. eCollection 2015.
10
Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.临床有效性:组合药物基因组学比单基因表型能更好地预测抗抑郁药反应和医疗保健利用情况。
Pharmacogenomics J. 2015 Oct;15(5):443-51. doi: 10.1038/tpj.2014.85. Epub 2015 Feb 17.